Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone marrow aspirates were subject to a negative-selection procedure to enrich for tumor...
Provenance — who produced it, who reused it
Linked to 47 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Clinical drug response can be predicted using baseline gene expr... 2014 · 959 cites
- Metabolic Signature Identifies Novel Targets for Drug Resistance... 2015 · 209 cites
- Identification and validation of potential prognostic lncRNA bio... 2015 · 181 cites
- Transient loss of Polycomb components induces an epigenetic canc... 2024 · 147 cites
- Prediction of high- and low-risk multiple myeloma based on gene... 2015 · 116 cites
- FTO promotes multiple myeloma progression by posttranscriptional... 2021 · 87 cites
- RECQ1 helicase is involved in replication stress survival and dr... 2017 · 75 cites
- CHEK1 and circCHEK1_246aa evoke chromosomal instability and indu... 2021 · 73 cites
39 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently